mhurhangee/ep-ind-claims huggingface dataset:
A compound of formula wherein, R 1 is -C 1-3 alkyl or -C 1-3 haloalkyl; R 2 is selected from -NHR 4, -C 1-5 alkyl, -C 1-5 haloalkyl, halogen and -S-C 1-3 alkyl; R 3 is a 5-12 membered heteroaryl, which group is substituted with -X-R 10 and optionally further substituted with one or more groups independently selected from R 9; R 4 is selected from -C 1-5 alkyl and 5-12 memebered heterocycloalkyl, which heterocycloalkyl can be optionally substituted with one or more groups independently selected from R 5; R 5 is selected from -C 1-5 alkyl, -C 1-5 haloalkyl and -C 1-3 alkylene-O-C 1-3 alkyl; R 9 is selected from -C 1-5 alkyl, -O-C 1-5 alkyl, -N(C 1-5 alkyl) 2, halogen, -C 1-3 alkylene-O-C 1-3 alkyl, -C 1-5 alkylene-N(-C 1-5 alkyl, -C 1-5 alkyl), 5-12 memebered heterocycloalkyl,wherein the heterocycloalkyl group can be optionally substituted with one or more groups independently selected from =O, -C 1-3 alkyl, or R 9 is selected from -C 6-10 aryl and 5-12 memebered heteroaryl, wherein the aryl and heteroaryl groups can be optionally and independently substituted with one or more groups selected from halogen, -C 1-3 alkyl, -O-C 1-3 alkyl, -C 1-3 haloalkyl, -O-C 1-3 haloalkyl, -N(C 1-5 alkyl, C 1-5 alkyl) and -NH-C 1-5 alkyl; X is -C 1-3 alkylene- or -O-; R 10 is -C 6-10 aryl or 5-12 membered heteroaryl, each of which groups can be optionally substituted with one or more groups selected from halogen, -C 1-3 alkyl, -O-C 1-3 alkyl, -C 1-3 haloalkyl, -O-C 1-3 haloalkyl; wherein the compounds of formula may be optionally be present in the form of salts. R 1 is -C 1-3 alkyl or -C 1-3 haloalkyl; R 2 is selected from -NHR 4, -C 1-5 alkyl, -C 1-5 haloalkyl, halogen and -S-C 1-3 alkyl; R 3 is a 5-12 membered heteroaryl, which group is substituted with -X-R 10 and optionally further substituted with one or more groups independently selected from R 9; R 4 is selected from -C 1-5 alkyl and 5-12 memebered heterocycloalkyl, which heterocycloalkyl can be optionally substituted with one or more groups independently selected from R 5; R 5 is selected from -C 1-5 alkyl, -C 1-5 haloalkyl and -C 1-3 alkylene-O-C 1-3 alkyl; R 9 is selected from -C 1-5 alkyl, -O-C 1-5 alkyl, -N(C 1-5 alkyl) 2, halogen, -C 1-3 alkylene-O-C 1-3 alkyl, -C 1-5 alkylene-N(-C 1-5 alkyl, -C 1-5 alkyl), 5-12 memebered heterocycloalkyl,wherein the heterocycloalkyl group can be optionally substituted with one or more groups independently selected from =O, -C 1-3 alkyl, or R 9 is selected from -C 6-10 aryl and 5-12 memebered heteroaryl, wherein the aryl and heteroaryl groups can be optionally and independently substituted with one or more groups selected from halogen, -C 1-3 alkyl, -O-C 1-3 alkyl, -C 1-3 haloalkyl, -O-C 1-3 haloalkyl, -N(C 1-5 alkyl, C 1-5 alkyl) and -NH-C 1-5 alkyl; X is -C 1-3 alkylene- or -O-; R 10 is -C 6-10 aryl or 5-12 membered heteroaryl, each of which groups can be optionally substituted with one or more groups selected from halogen, -C 1-3 alkyl, -O-C 1-3 alkyl, -C 1-3 haloalkyl, -O-C 1-3 haloalkyl;
A method of guiding a Cas9 polypeptide to a target DNA, the method comprising contacting the target DNA in a single-cell eukaryotic organism, an animal cell, a plant cell, a cell from a mammal or a cell from a human wherein the cell is in vitro or ex vivo, with a complex comprising: (a) a Cas9 polypeptide and (b) a DNA-targeting RNA comprising (i) a DNA-targeting segment comprising a nucleotide sequence that is complementary to a sequence in the target DNA, and (ii) a protein-binding segment that interacts with said Cas9 polypeptide, wherein the protein-binding segment comprises two complementary stretches of nucleotides that hybridize to form a double stranded RNA (dsRNA) duplex, wherein said method is not a process for modifying the germ line genetic identity of human beings. (a) a Cas9 polypeptide and (b) a DNA-targeting RNA comprising (i) a DNA-targeting segment comprising a nucleotide sequence that is complementary to a sequence in the target DNA, and (ii) a protein-binding segment that interacts with said Cas9 polypeptide, wherein the protein-binding segment comprises two complementary stretches of nucleotides that hybridize to form a double stranded RNA (dsRNA) duplex, (i) a DNA-targeting segment comprising a nucleotide sequence that is complementary to a sequence in the target DNA, and (ii) a protein-binding segment that interacts with said Cas9 polypeptide, wherein the protein-binding segment comprises two complementary stretches of nucleotides that hybridize to form a double stranded RNA (dsRNA) duplex,
A positive electrode for a lithium secondary battery, comprising lithium manganese iron phosphate and a lithium-nickel-manganese-cobalt composite oxide; characterized in that an average particle size of particles of the lithium manganese iron phosphate is smaller than an average particle size of particles of the lithium-nickel-manganese-cobalt composite oxide.
A refrigeration and/or freezer device having at least one housing, which at least sectionally surrounds at least one chamber cooled in operation of the device, wherein the housing and/or the at least one closure element thereof comprises a heat insulation material and wherein the housing and/or the closure element thereof further comprises at least one reinforcement member for mechanical stabilization of the housing or the closure element, characterized in that the reinforcement member is sectionally or completely not in connection with the heat insulation material but loosely accommodated in at least one support component, which is per se accommodated in the heat insulation material, wherein the reinforcement member is accommodated in the support component in such a way that it is moveable relative to this component, and in that the reinforcement member has an elongated shape and is formed as a hollow profile.
A monoclonal antibody (mAb) or fragment thereof that binds with specificity to surfactant protein A SP-R210 receptor, comprising: a variable heavy chain sequence comprising: a) a heavy chain complementarity determining region 1 (P2H10-HCDR1) comprising the sequence GYIFSDYYMR (SEQ ID NO:3); and b) a heavy chain complementarity determining region 2 (P2H10-HCDR2) comprising the sequence DINPKNGDTFYNQKFKGK (SEQ ID NO:4); and c) a heavy chain complementarity determining region 3 (P2H10-HCDR3) comprising the sequence REGD (SEQ ID NO:5); and a variable light chain sequence comprising: d) a light chain complementarity determining region 1 (P2H10-LCDR1) comprising the sequence RSSQTILHSNGNTYLE (SEQ ID NO:6); and e) a light chain complementarity determining region 2 (P2H10-LCDR2) comprising the sequence KVSKRFS (SEQ ID NO:7): and f) a light chain complementarity determining region 3 (P2H10-LCDR3) comprising the sequence LQGSHVPLT (SEQ ID NO:8); and wherein the monoclonal antibody or fragment of binds with specificity to only SP-R210 S isoform of the SP-R210 receptor. a variable heavy chain sequence comprising: a) a heavy chain complementarity determining region 1 (P2H10-HCDR1) comprising the sequence GYIFSDYYMR (SEQ ID NO:3); and b) a heavy chain complementarity determining region 2 (P2H10-HCDR2) comprising the sequence DINPKNGDTFYNQKFKGK (SEQ ID NO:4); and c) a heavy chain complementarity determining region 3 (P2H10-HCDR3) comprising the sequence REGD (SEQ ID NO:5); and a variable light chain sequence comprising: d) a light chain complementarity determining region 1 (P2H10-LCDR1) comprising the sequence RSSQTILHSNGNTYLE (SEQ ID NO:6); and e) a light chain complementarity determining region 2 (P2H10-LCDR2) comprising the sequence KVSKRFS (SEQ ID NO:7): and f) a light chain complementarity determining region 3 (P2H10-LCDR3) comprising the sequence LQGSHVPLT (SEQ ID NO:8); and wherein the monoclonal antibody or fragment of binds with specificity to only SP-R210 S isoform of the SP-R210 receptor. a) a heavy chain complementarity determining region 1 (P2H10-HCDR1) comprising the sequence GYIFSDYYMR (SEQ ID NO:3); and b) a heavy chain complementarity determining region 2 (P2H10-HCDR2) comprising the sequence DINPKNGDTFYNQKFKGK (SEQ ID NO:4); and c) a heavy chain complementarity determining region 3 (P2H10-HCDR3) comprising the sequence REGD (SEQ ID NO:5); and d) a light chain complementarity determining region 1 (P2H10-LCDR1) comprising the sequence RSSQTILHSNGNTYLE (SEQ ID NO:6); and e) a light chain complementarity determining region 2 (P2H10-LCDR2) comprising the sequence KVSKRFS (SEQ ID NO:7): and f) a light chain complementarity determining region 3 (P2H10-LCDR3) comprising the sequence LQGSHVPLT (SEQ ID NO:8); and wherein the monoclonal antibody or fragment of binds with specificity to only SP-R210 S isoform of the SP-R210 receptor.
A method for providing software for use by a control unit of a vehicle, such as more especially a motor vehicle or motor bike, in which before the software is used by the control unit, it is signed against falsification using the secret or private key of a software signature site according to a public key method, and the signed software is checked for authenticity using the public key which is complementary to the secret key of the software signature site, characterised in that - a software signature certificate is generated using the public key of the software signature site and the secret key of a supervisory authority, a so-called trust centre, according to a public key process, - a clearing code site signature certificate is generated using the secret key of the supervisory authority, the trust centre, according to a public key method, - the clearing code site signature certificate, the software signature certificate, the clearing code data and its signature as well as the software and its signature are stored in the control unit, and - the software signature certificate has been provided with one or more validity restrictions, such as more especially a restriction to one or more types of control unit. - a software signature certificate is generated using the public key of the software signature site and the secret key of a supervisory authority, a so-called trust centre, according to a public key process, - a clearing code site signature certificate is generated using the secret key of the supervisory authority, the trust centre, according to a public key method, - the clearing code site signature certificate, the software signature certificate, the clearing code data and its signature as well as the software and its signature are stored in the control unit, and - the software signature certificate has been provided with one or more validity restrictions, such as more especially a restriction to one or more types of control unit.
A wearable device wearable by a user for measuring skin conductance of the user, the wearable device comprising: - at least two skin conductance electrodes for contacting skin of the user, and - an elastic material portion, wherein the elastic material portion surrounds and circumferentially encloses the skin conductance electrodes and forms a material surface, wherein the elastic material of the elastic material portion is non-permeable for gaseous and liquid substances, and wherein the elastic material portion is arranged such that an air pocket is sealed off in the vicinity of the skin conductance electrodes and a fluid film is generated between the skin and the skin conductance electrodes, when the wearable device is worn by the user and the skin conductance electrodes contact the skin, wherein the skin conductance electrodes protrude between 50 to 1000 micrometer from the material surface. - at least two skin conductance electrodes for contacting skin of the user, and - an elastic material portion, wherein the elastic material portion surrounds and circumferentially encloses the skin conductance electrodes and forms a material surface, wherein the elastic material of the elastic material portion is non-permeable for gaseous and liquid substances, and wherein the elastic material portion is arranged such that an air pocket is sealed off in the vicinity of the skin conductance electrodes and a fluid film is generated between the skin and the skin conductance electrodes, when the wearable device is worn by the user and the skin conductance electrodes contact the skin, wherein the skin conductance electrodes protrude between 50 to 1000 micrometer from the material surface.
A compound, or a pharmaceutically acceptable salt thereof, of formula I: in which: R 1 is selected from hydrogen, amino and hydroxy-substituted C 1-2 alkyl; R 2 is hydrogen; R 3 is selected from C 1-2 alkyl and halo-substituted-C 1-2 alkyl; R 4 is hydrogen; R 5 is selected from hydrogen and halo; and R 6 is selected from hydrogen and halo. R 1 is selected from hydrogen, amino and hydroxy-substituted C 1-2 alkyl; R 2 is hydrogen; R 3 is selected from C 1-2 alkyl and halo-substituted-C 1-2 alkyl; R 4 is hydrogen; R 5 is selected from hydrogen and halo; and R 6 is selected from hydrogen and halo.
A terminal apparatus compatible with LTE [Long Term Evolution] or LTE-A [LTE-advanced], comprising: a transmission section configured to transmit a sounding reference signal, SRS; and a detection section configured to detect a request signal for requesting a transmission of the SRS;, wherein a minimum time separation exists between the request signal and the transmission of the SRS; characterized in that an SRS transmission timing is further set on the basis of an offset obtained by comparison of buffer status report information of the terminal apparatus with a set threshold value. a transmission section configured to transmit a sounding reference signal, SRS; and a detection section configured to detect a request signal for requesting a transmission of the SRS;, wherein a minimum time separation exists between the request signal and the transmission of the SRS; characterized in that an SRS transmission timing is further set on the basis of an offset obtained by comparison of buffer status report information of the terminal apparatus with a set threshold value.
A power supply circuit, comprising: a battery; a load (3, 4) to which power is supplied from the battery; a relay (22a, 22b, 22c) that is provided between the battery and the load (3, 4); a relay control unit to which both ends of a relay coil provided in the relay (22a, 22b, 22c) are connected, said relay control unit being configured to control a current flowing through the relay coil, thereby controlling a turning on and off of the relay (22a, 22b, 22c), and to turn on the relay (22a, 22b, 22c) according to a turning on of an ignition switch; a service plug that is detachably provided on a current path from the battery to the load (3, 4), wherein when the service plug is detached, the current path from the battery to the load (3, 4) is interrupted and when the service plug is attached, the current path from the battery to the load (3, 4) is closed through the service plug; and an interlock switch that is configured to detect the attachment and detachment of the service plug such that the interlock switch is turned off when the service plug is detached and is turned on when the service plug is attached, wherein the load (3, 4) and the relay control unit are configured to be disposed at the front of a vehicle, and the battery, the relay (22a, 22b, 22c), the service plug and the interlock switch are configured to be disposed at the rear of the vehicle, characterized in that the interlock switch is connected between the relay control unit and the relay coil. a battery; a load (3, 4) to which power is supplied from the battery; a relay (22a, 22b, 22c) that is provided between the battery and the load (3, 4); a relay control unit to which both ends of a relay coil provided in the relay (22a, 22b, 22c) are connected, said relay control unit being configured to control a current flowing through the relay coil, thereby controlling a turning on and off of the relay (22a, 22b, 22c), and to turn on the relay (22a, 22b, 22c) according to a turning on of an ignition switch; a service plug that is detachably provided on a current path from the battery to the load (3, 4), wherein when the service plug is detached, the current path from the battery to the load (3, 4) is interrupted and when the service plug is attached, the current path from the battery to the load (3, 4) is closed through the service plug; and an interlock switch that is configured to detect the attachment and detachment of the service plug such that the interlock switch is turned off when the service plug is detached and is turned on when the service plug is attached, wherein the load (3, 4) and the relay control unit are configured to be disposed at the front of a vehicle, and the battery, the relay (22a, 22b, 22c), the service plug and the interlock switch are configured to be disposed at the rear of the vehicle, characterized in that the interlock switch is connected between the relay control unit and the relay coil.
A liquid ejection apparatus comprising a liquid container configured to be mounted to/removed from a mount portion of the liquid ejection apparatus including: a box; a head that ejects liquid; a moving body that is equipped with the head, and moves along a X direction in the box, and when the liquid is not ejected from the head, stands by in an end portion on a +X direction side in the box; a mount portion provided on the moving body; and a rotation lever provided at a position on the +X direction side in the mount portion so as to be rotatable centered on a shaft line along a Y direction, when the vertical direction is assumed to be a Z direction, a direction orthogonal to the Z direction is assumed to be the X direction, a direction orthogonal to both the Z direction and the X direction is assumed to be the Y direction, the vertical upward direction in the Z direction is assumed to be a +Z direction, while the vertical downward direction is assumed to be a -Z direction, the positive direction in the X direction is assumed to be the +X direction, while the negative direction is assumed to be a -X direction, and a state where the liquid container is mounted on the mount portion is assumed to be a mounted state, the liquid container in the mounted state including: a +Z direction side wall portion positioned on the +Z direction side; a +X direction side wall portion positioned on the +X direction side; and a hook portion provided on one of the +Z direction side wall portion and the +X direction side wall portion, the hook portion configured to engage with an engagement portion constituted by one of: an outer face on the +X direction side in the moving body, an outer face on the +X direction side in the rotation lever, and a gap in the Z direction formed between a wall on the +X direction side of the moving body and the rotation lever so as to restrict movement of the liquid container from the mount portion in the +Z direction. a +Z direction side wall portion positioned on the +Z direction side; a +X direction side wall portion positioned on the +X direction side; and a hook portion provided on one of the +Z direction side wall portion and the +X direction side wall portion, the hook portion configured to engage with an engagement portion constituted by one of: an outer face on the +X direction side in the moving body, an outer face on the +X direction side in the rotation lever, and a gap in the Z direction formed between a wall on the +X direction side of the moving body and the rotation lever an outer face on the +X direction side in the moving body, an outer face on the +X direction side in the rotation lever, and a gap in the Z direction formed between a wall on the +X direction side of the moving body and the rotation lever so as to restrict movement of the liquid container from the mount portion in the +Z direction.
Compound of formula in which: ▪ R 1 represent a -(CH 2) 4 C OH group; ▪ R 2 represents: - a phenyl group non-substituted or substituted by one or more substituents chosen among: - a C 1 to C 6 alkoxy group, linear or branched; - a halogen atom; - a C 1 to C 5 linear or branched hydrocarbon group; - a C 1 to C 5 linear or branched hydrocarbon group, substituted by one or more halogen atoms; - a heterocycle aromatic group with 5 or 6 members, comprising 1, 2 or 3 heteroatoms, identical or different, chosen among nitrogen, oxygen or sulfur; enantiomers and diastereoisomers thereof and the addition salts thereof with pharmaceutically acceptable bases or acids. ▪ R 1 represent a -(CH 2) 4 C OH group; ▪ R 2 represents: - a phenyl group non-substituted or substituted by one or more substituents chosen among: - a C 1 to C 6 alkoxy group, linear or branched; - a halogen atom; - a C 1 to C 5 linear or branched hydrocarbon group; - a C 1 to C 5 linear or branched hydrocarbon group, substituted by one or more halogen atoms; - a heterocycle aromatic group with 5 or 6 members, comprising 1, 2 or 3 heteroatoms, identical or different, chosen among nitrogen, oxygen or sulfur; - a phenyl group non-substituted or substituted by one or more substituents chosen among: - a C 1 to C 6 alkoxy group, linear or branched; - a halogen atom; - a C 1 to C 5 linear or branched hydrocarbon group; - a C 1 to C 5 linear or branched hydrocarbon group, substituted by one or more halogen atoms; - a C 1 to C 6 alkoxy group, linear or branched; - a halogen atom; - a C 1 to C 5 linear or branched hydrocarbon group; - a C 1 to C 5 linear or branched hydrocarbon group, substituted by one or more halogen atoms; - a heterocycle aromatic group with 5 or 6 members, comprising 1, 2 or 3 heteroatoms, identical or different, chosen among nitrogen, oxygen or sulfur;
A fuel cell system which comprises - a fuel cell which decomposes hydrocarbon-based fuel in order to produce electrical energy, - a fuel tank, from which fuel can be fed into the fuel cell, - a treatment unit for treatment of decomposition products, and - a separation means adapted to direct decomposition products of the fuel cell therethrough and into the treatment unit, the separation means is selective with regard to the decomposition products to be treated, the treatment unit comprising an agent which is capable of reacting with the carbon dioxide which is generated in the fuel cell, and with which it is possible to transform the carbon dioxide into a liquid or solid compound, characterized in that - the fuel tank and the treatment unit are at least partly separated from each other by a movable shared wall, which is made of a flexible and elastic material in order to even out the pressure difference, the volume difference or both of them, between the fuel tank and the treatment unit. - a fuel cell which decomposes hydrocarbon-based fuel in order to produce electrical energy, - a fuel tank, from which fuel can be fed into the fuel cell, - a treatment unit for treatment of decomposition products, and - a separation means adapted to direct decomposition products of the fuel cell therethrough and into the treatment unit, the separation means is selective with regard to the decomposition products to be treated, the treatment unit comprising an agent which is capable of reacting with the carbon dioxide which is generated in the fuel cell, and with which it is possible to transform the carbon dioxide into a liquid or solid compound, characterized in that - the fuel tank and the treatment unit are at least partly separated from each other by a movable shared wall, which is made of a flexible and elastic material in order to even out the pressure difference, the volume difference or both of them, between the fuel tank and the treatment unit.